Month: April 2026

Release – Newsmax to Report First Quarter 2026 Financial Results

Posted on by [email protected]
Newsmax logo image

Research News and Market Data on NMAX

April 23, 2026

BOCA RATON, FL / ACCESS Newswire / April 23, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that the Company will report financial results for the first quarter ended March 31, 2026 on Thursday, May 14, 2026, after the U.S. stock market closes.

Management will host a conference call at 4:30 PM ET the same day to discuss the results. The live webcast and replay will be available on the Newsmax Investor Relations website at ir.newsmax.com.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 24 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts

Newsmax Investor Relations
[email protected]

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

Release – The GEO Group Announces Date for First Quarter 2026 Earnings Release and Conference Call

Posted on by [email protected]

Research News and Market Data on GEO

April 23, 2026

PDF Version

  • Earnings Release Scheduled for Wednesday, May 6, 2026 Before the Market Opens
  • Conference Call Scheduled for Wednesday, May 6, 2026 at 11:00 AM (Eastern Time)

BOCA RATON, Fla.–(BUSINESS WIRE)–Apr. 23, 2026– The GEO Group, Inc. (NYSE:GEO) (“GEO”) will release its first quarter 2026 financial results on Wednesday, May 6, 2026 before the market opens. GEO has scheduled a conference call and simultaneous webcast for 11:00 AM (Eastern Time) on Wednesday, May 6, 2026.

To participate in the teleconference, please contact one of the following numbers 5 minutes prior to the scheduled start time:

1-877-250-1553 (U.S.)
1-412-542-4145 (International)

In addition, a live audio webcast of the conference call may be accessed on the Webcasts section of GEO’s investor relations home page at investors.geogroup.com. A webcast replay will remain available on the website for one year.

A telephonic replay will also be available through May 13, 2026. The replay numbers are 1-855-669-9658 (U.S.) and 1-412-317-0088 (International). The passcode for the telephonic replay is 8366763. If you have any questions, please contact GEO at 1-866-301-4436.

Pablo E. Paez, 1-866-301-4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Release – Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Posted on by [email protected]

Research News and Market Data on TNXP

April 23, 2026 7:00am EDTDownload as PDF

TNX-1700 (TFF2-albumin fusion protein) reversed aging-associated gastric inflammation and significantly attenuated tumor progression in aged gastric microenvironment in preclinical models

TNX-1700 exhibited dose-independent, linear pharmacokinetics in animals

TNX-4700 (human anti-BTLA monoclonal antibody) demonstrated potent, high-affinity binding and functional antagonism

BERKELEY HEIGHTS, N.J., April 23, 2026 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, today announced an oral presentation and two poster presentations on its preclinical immuno-oncology portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22, 2026, in San Diego, California.

“We are pleased to report encouraging preclinical data on our TFF2-albumin fusion protein (TNX-1700) and our anti-BTLA monoclonal antibody (mAb) (TNX-4700) at AACR,” said Bruce Daugherty, PhD, MBA, Executive Vice President of Research at Tonix Pharmaceuticals. “TNX-1700 and TNX-4700 are investigational immuno-oncology candidates in pre-clinical development. TNX-1700 is in development for the treatment of gastric and colorectal cancer in combination with PD-1 inhibitors. TNX-4700 is in development for the treatment of potentially several cancers since its ligand HVEM is expressed and/or upregulated in the tumor microenvironment and generally correlates with reduced overall survival.”

Abstract #: 6822 Oral Presentation: “TFF2 Deficiency Amplifies IL-1β–Driven Inflammation and Promotes Aging-Associated Gastric Tumor Progression”

  • Presenting author: Shuang Li, MD, PhD, Postdoctoral Research Scientist in the Timothy C. Wang, MD, Laboratory at the Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center

Aging is a major risk factor for gastric cancer, but the underlying mechanisms remain poorly defined. The stomach undergoes profound epithelial and immune remodeling during aging. TFF2 is a mucosal protective factor implicated in epithelial repair and immune regulation. However, whether TFF2 regulates age-associated inflammation and tumor progression remains unknown.

TFF2-expressing epithelial cells were reduced in the stomachs of aged mice compared to young mice, with corresponding reductions in tissue and circulating TFF2 levels. Decline of TFF2 led to elevated IL-1β and promoted gastric inflammaging. The murine version of TNX-1700 (mTNX-1700 or TFF2-MSA) treatment reversed aging-associated inflammation. The aged stomach exhibited increased susceptibility to tumor progression. Myeloid-derived stem cells (MDSCs) accumulated and overexpressed IL-1β, interacting with IL-1R1⁺ cancer associated fibroblasts (CAFs). mTNX-1700 attenuated tumor progression in the aged gastric microenvironment.

Poster Presentation #7940: “Pharmacokinetics of TNX-1700 in Non-Human Primates and Human FcRn/Serum Albumin Transgenic Mice”

  • Presenting author: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

TNX-1700 was evaluated in double-transgenic mice expressing human FcRn and human serum albumin (HSA) and in non-human primates. All animals survived without clinical signs or greater than 10% body-weight loss. TNX-1700 exhibited dose-independent, linear pharmacokinetics, with comparable pharmacokinetic profiles and exposure observed across species and doses. TNX-1700 substantially extends the half-life of TFF2 and achieves durable systemic exposure, supporting its potential as a therapeutic candidate for gastric cancer.

Poster Presentation #6550: In Vitro Characterization of Fully Human Antagonistic Anti-BTLA Monoclonal Antibodies

  • Presenting author: Bruce Daugherty, PhD, MBA, Executive Vice President of Research, Tonix

B and T Lymphocyte Attenuator (BTLA) is a promising target in immuno-oncology since its ligand HVEM (herpesvirus entry mediator) is expressed in and upregulated in the tumor microenvironment of many cancers and generally correlates with reduced overall survival. Targeting BTLA offers opportunities for cancer immunotherapy and may demonstrate additive or synergistic activity when combined with other checkpoint antagonists, potentially overcoming resistance mechanisms and improving clinical outcomes.

Tonix studied several anti-BTLA mAbs, which demonstrated potent, high-affinity binding and functional antagonism of BTLA in vitro. Antagonists with reduced FcgRI binding and no binding to FcgRIIB may improve pharmacokinetics and confer a reduced risk of FcR-dependent adverse events, such as cytokine release syndrome or other immune-mediated toxicities.

Copies of the two poster presentations are available under the Scientific Presentations tab on the Tonix website at www.tonixpharma.com.

About Trefoil Factor Family Member 2 (TFF2)
Human TFF2 is a secreted protein expressed in gastrointestinal mucosa where it functions to protect and repair the mucosal lining. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several mechanisms, including its activity as a partial agonist of CXCR4 that modulates myeloid cell trafficking to reduce accumulation of immunosuppressive neutrophils.

About TNX-1700
TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical and pre-Investigational New Drug (IND) stage of development as a treatment of gastric and colorectal cancer in combination with PD-1 blockade.1 The Company in-licensed TFF2 technology from Columbia University. TNX-1700 is an immunotherapy being developed to treat gastric and colorectal cancers in combination with PD-1 blockers. Results of preclinical testing demonstrated that a mouse version of TNX-1700 was able to evoke an increase in anti-tumor immunity in combination with anti-PD-1 in several mouse models of gastric cancer by reducing immunosuppressive neutrophils and activating anti-tumoral CD8+ T cell responses. TNX-1700 administered as both monotherapy and in combination with anti-PD-1 dramatically reduced metastasis and increased survival in these models; these findings were recently published.1 TNX-1700 addresses a central mechanism of therapeutic resistance to anti-PD-1 therapy in gastric cancer by targeting the CXCR4-driven myeloid axis to normalize cancer-induced myelopoiesis and reprogram the tumor microenvironment.

About BTLA
BTLA (B and T lymphocyte attenuator) is a protein on the surface of tumor infiltrating lymphocytes. Targeting BTLA is a promising target in immuno-oncology since its ligand HVEM is expressed and/or upregulated in the tumor microenvironment of many cancers including melanoma, non-small cell lung cancer, colorectal cancer, gastric cancer, glioblastoma, and prostate cancer and generally correlates with reduced overall survival. Targeting BTLA offers opportunities for cancer immunotherapy and may demonstrate additive or synergistic effects when combined with other checkpoint antagonists, potentially overcoming resistance mechanisms and improving clinical outcomes.

About TNX-4700
Tonix is developing TNX-4700 (anti-BTLA) mAb for immuno-oncology indications. The mAb technology was licensed from Curia.

Citations:

  1. Qian J, et al. Cancer Cell. 2025. 43(8):1512-1529.e11.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder/acute stress reaction. Tonix is also advancing a pipeline of immunology programs, including TNX-4800, a Phase 2 ready long-acting human anti-Borrelia OspA monoclonal antibody (mAb) for the prevention of Lyme disease in the U.S., and TNX-1500, a Phase 2 ready third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. In addition, the Company is progressing TNX-2900 (intranasal potentiated oxytocin), which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.

*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA® and any of our approved products; risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
[email protected]
(862) 799-8599

Brian Korb
astr partners
(917) 653-5122
[email protected]

Media Contacts
Deborah Elson
Tonix Pharmaceuticals
[email protected]

Ray Jordan
Putnam Insights
[email protected]

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released April 23, 2026

Release – Direct Digital Holdings Announces Reverse Stock Split

Posted on by [email protected]

Research News and Market Data on DRCT

HOUSTON, April 23, 2026 /PRNewswire/ — Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”) and Orange 142, LLC (“Orange 142”), today announced a 4-to-1 reverse stock split of all classes of its common stock. The Company expects the Class A common stock to begin trading on a split-adjusted basis on The Nasdaq Stock Market as of the commencement of trading on April 27, 2026. The reverse stock split is intended to allow the Company to maintain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share.

As previously announced, Direct Digital Holdings’ Board of Directors and its stockholders approved one or more reverse stock splits for up to a ratio of 250-to-1 to be effected before December 26, 2026, with the authorization to determine the number of reverse stock splits and the final ratios for each such reverse stock splits having been granted to, and determined by, the Board. The 4-to-1 reverse stock split follows the 55-to-1 reverse stock split effected on January 12, 2026. 

As a result of the reverse stock split, every four shares of the Company’s common stock issued and outstanding will be automatically converted into one share of common stock, with no change in the $0.001 par value per share or authorized number of shares of common stock. The number of outstanding shares of Class A common stock, which is traded on Nasdaq, will be reduced from approximately 2.8 million to approximately 0.7 million, and the number of outstanding shares of Class B common stock, which is exchangeable and votes with the Class A common stock, will be reduced from approximately 0.17 million to approximately 0.04 million.

Mark Walker, Chief Executive Officer of Direct Digital Holdings, commented, “Our Nasdaq listing is an important asset, and this reverse split positions us to continue to meet the listing requirements of Nasdaq and maintain an efficient public float that supports institutional and long-term investor interest. We are optimistic about our future as the team focuses on leveraging our deep industry experience and AI capabilities to execute our growth strategy.” 

The Company’s Class A common stock will continue to trade on Nasdaq under the symbol “DRCT.” The new CUSIP number for the Class A common stock following the reverse split is 25461T303.

No fractional shares will be issued if, as a result of the reverse stock split, a stockholder would otherwise become entitled to a fractional share because the number of shares of common stock they hold before the reverse stock split is not evenly divisible by the split ratio. Instead, each stockholder will be entitled to receive a proportional cash payment in lieu of a fractional share. The Company’s transfer agent, Equiniti Trust Company, is acting as the exchange and paying agent for the reverse stock split. The Company does not expect that stockholders holding their shares in book-entry form or through a bank, broker or other nominee need to take any action in connection with the reverse stock split. Beneficial holders are encouraged to contact their bank, broker or other nominee with any procedural questions. Additional information concerning the reverse stock split can be found in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on December 15, 2025.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws that are subject to certain risks, trends and uncertainties. We use words such as “could,” “would,” “may,” “might,” “will,” “expect,” “likely,” “believe,” “continue,” “anticipate,” “estimate,” “intend,” “plan,” “project” and other similar expressions to identify forward-looking statements, but not all forward-looking statements include these words. All of our forward-looking statements involve estimates and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Accordingly, any such statements are qualified in their entirety by reference to the information described under the caption “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “Form 10-K”) and subsequent periodic and or current reports filed with the Securities and Exchange Commission (the “SEC”).

The forward-looking statements contained in this press release are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. As you read and consider this press release, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond our control) and assumptions.

Although we believe that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect our actual operating and financial performance and cause our performance to differ materially from the performance expressed in or implied by the forward-looking statements. We believe these factors include, but are not limited to, the following: the restrictions and covenants imposed upon us by our credit facilities; the substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing; our ability to secure additional financing to meet our capital needs; our ability to maintain compliance with the listing standards of the Nasdaq Capital Market; our ability to realize the benefits of our strategic shift to focusing on driving digital marketing spend among buy side and new enterprise customers; any significant fluctuations caused by our high customer concentration; risks related to non-payment by our clients; reputational and other harms caused by our failure to detect advertising fraud; operational and performance issues with our platform, whether real or perceived, including a failure to respond to technological changes or to upgrade our technology systems; restrictions on the use of third-party “cookies,” mobile device IDs or other tracking technologies, which could diminish our platform’s effectiveness; unfavorable publicity and negative public perception about our industry, particularly concerns regarding data privacy and security relating to our industry’s technology and practices, and any perceived failure to comply with laws and industry self-regulation; our failure to manage our growth effectively; the difficulty in identifying and integrating any future acquisitions or strategic investments; any changes or developments in legislative, judicial, regulatory or cultural environments related to information collection, use and processing; challenges related to our buy-side clients that are destination marketing organizations and that operate as public/private partnerships; any strain on our resources or diversion of our management’s attention as a result of being a public company; the intense competition of the digital advertising industry and our ability to effectively compete against current and future competitors; any significant inadvertent disclosure or breach of confidential and/or personal information we hold, or of the security of our or our customers’, suppliers’ or other partners’ computer systems; as a holding company, we depend on distributions from Direct Digital Holdings, LLC to pay our taxes, expenses (including payments under the Tax Receivable Agreement) and any amount of any dividends we may pay to the holders of our common stock; any failure by us to maintain or implement effective internal controls or to detect fraud; and other factors and assumptions discussed in our Form 10-K and subsequent periodic and current reports we may file with the SEC.

Should one or more of these risks or uncertainties materialize or should any of these assumptions prove to be incorrect, our actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement contained in this press release to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. New factors that could cause our business not to develop as we expect emerge from time to time, and it is not possible for us to predict all of them. Further, we cannot assess the impact of each currently known or new factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. 

About Direct Digital Holdings

Direct Digital Holdings (Nasdaq: DRCT) combines cutting-edge sell-side and buy-side advertising solutions, providing data-driven digital media strategies that enhance reach and performance for brands, agencies, and publishers of all sizes. Our sell-side platform, Colossus SSP, offers curated access to premium, growth-oriented media properties throughout the digital ecosystem. On the buy-side, Orange 142 delivers customized, audience-focused digital marketing and advertising solutions that enable mid-market and enterprise companies to achieve measurable results across a range of platforms, including programmatic, search, social, CTV, and influencer marketing. With extensive expertise in high-growth sectors such as Energy, Healthcare, Travel & Tourism, and Financial Services, our teams deliver performance strategies that connect brands with their ideal audiences.

At Direct Digital Holdings, we prioritize personal relationships by humanizing technology, ensuring each client receives dedicated support and tailored digital marketing solutions regardless of company size. This empowers everyone to thrive by generating billions of monthly impressions across display, CTV, in-app, and emerging media channels through advanced targeting, comprehensive data insights, and cross-platform activation. DDH is “Digital advertising built for everyone.”

Contacts:

Investors:
IMS Investor Relations
Walter Frank/Jennifer Belodeau
(203) 972-9200
[email protected]

SOURCE Direct Digital Holdings

Release – Century Lithium Advances Demonstration Plant Relocation to Tonopah and Provides Reagent Cost Structure Update

Posted on by [email protected]
Century Lithium

Research News and Market Data on CYDVF

Demonstration Plant Commissioning Targeted for H2 2026; Company’s Chlor-Alkali Process Uses Salt-Based Reagents with No Direct Exposure to Rising Global Sulfur and Sulfuric Acid Prices

April 23, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or the “Company”) is pleased to provide an update on the relocation of its Lithium Extraction Facility (“Demonstration Plant”) to the Company’s site in Tonopah, Nevada, USA. Current market conditions also highlight the competitive advantage of the Company’s 100%-owned Angel Island lithium project (“Angel Island”) in Esmeralda County, Nevada and its integrated chlor-alkali process as global sulfur and sulfuric acid prices rise.

“During the last five years, Century Lithium developed an integrated process flowsheet that successfully produced battery-grade lithium carbonate from Angel Island claystone. The patent-pending process uses salt, rather than sulfur-derived reagents, which distinguishes Angel Island from spodumene and most sedimentary lithium projects globally,” said Bill Willoughby, President and CEO of Century Lithium. “Moving the Demonstration Plant to Tonopah lets us show the operating benefits of our chlor-alkali process at a moment when sulfur demand and related reagent costs are rising. Our process was designed for its compatibility with our Angel Island lithium deposit and regionally obtainable resources. As pressures on international supply chains increase, that advantage becomes increasingly meaningful for our shareholders and future customers.”

Demonstration Plant: Progress and Planned Work at Tonopah

The Demonstration Plant operated at the Company’s Amargosa Valley facility for five years, producing battery-grade lithium carbonate and validating the integrated chlor-alkali flowsheet for Angel Island. Relocation to Tonopah is proceeding as planned. Equipment relocation, construction of a new process building, and application for a Nevada Water Pollution Control Permit are all in progress, with commissioning targeted for the second half of 2026.

Upon completion, the Company plans to conduct structured metallurgical testing per the recommendations of the 2026 Feasibility Study (described below), including full test runs on claystone zones 1 and 2. Bench-scale testing reported in the Feasibility Study indicates the deeper claystone performs as well as, or better than, the bulk samples of surface material used in earlier runs. The Company also plans to evaluate improvements to leaching, direct lithium extraction (“DLE”), and lithium carbonate and hydroxide production.

The Demonstration Plant will also serve as a showcase of salt-based lithium extraction for government agencies, community stakeholders, and potential funding partners. The Company is pursuing federal critical-minerals funding opportunities, including evaluation of the potential recovery of additional critical elements from Angel Island leach solutions as identified in the Feasibility Study.

Century Lithium’s Chlor-Alkali Process: Salt as the Foundation

Angel Island is built around a patent-pending chlor-alkali process in which hydrochloric acid (“HCl”) and sodium hydroxide (“NaOH”) are generated on-site from sodium chloride (“NaCl”) and electricity. HCl leaches lithium from Angel Island claystone; NaOH provides pH control throughout leaching, filtration, and DLE. Both reagents are continuously regenerated as co-products of the electrolytic cells, closing the loop and eliminating reliance on external acid supply chains.

The process does not use sulfuric acid and produces no sulfate by-products. The primary inputs are NaCl and electricity which are stable, domestically available, and structurally uncorrelated to sulfur markets. As set out in the 2026 Feasibility Study, NaOH surplus to process requirements, which is expected to be significant, available for sale as an economic by-product.

Global Sulfur Market Conditions: Why the Process Design Matters Now

Global sulfur markets are experiencing an extraordinary dislocation with direct consequences for agriculture and basic industries including metals. China’s spot sulfur price of US$950/tonne represents a 283% increase from approximately US$248/t in January 2025.1 In the United States, Tampa contract sulfur prices have surged from US$69 per long ton at the start of 2024 to a projected US$475 to $520 per long ton under Q1 2026 contracts, an increase of approximately 600% in under two years.2 U.S. sulfuric acid prices have followed, rising from US$85 per tonne in early 2024 to US$146 per tonne by March 2026.3

2026 Feasibility Study

The 2026 Feasibility Study on Angel Island, prepared by Mineral Property Development, LLC (“MPDI”), Global Resource Engineering, Ltd. (“GRE”) and SRK Incorporated (“SRK”) in accordance with National  Instrument 43-101 (NI 43-101), confirms that the chlor-alkali process’s structural insulation from these supply chain forces underpins strong project economics with an after-tax NPV of US$4.01 billion and average operating costs of US$4,389/t of lithium carbonate.

The complete NI 43-101 technical report has been filed on SEDAR+ at www.sedarplus.ca. Investors are encouraged to read the technical report in its entirety for all material assumptions and qualifying factors.

Qualified Person

The scientific and technical information contained in this news release has been reviewed and approved by Todd S. Fayram, MMSA-QP, Chief Technical Officer of Century Lithium, a non-independent Qualified Person under NI 43-101.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island lithium project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process for the on-site production of battery-grade lithium carbonate to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE” the OTCQX under the symbol “CYDVF”, and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be under the Company’s profile at www.sedarplus.ca. The Company expressly disclaims any obligation to update-forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

1 SunSirs, “Pressure on the Sulphur Industry Chain Mounts Sharply,” 16 April 2026.
2 U.S. Geological Survey, Mineral Commodity Summaries 2025, “Sulfur”; Argus Media, “Viewpoint: Sulfur costs to support amsul prices in 2026,” 2 January 2026.
3 IMARC Group, Sulphuric Acid Prices, Trend, Chart, Index and Forecast, Q1 2026.

Release – Travelzoo Reports First Quarter 2026 Results

Posted on by [email protected]
Travelzoo logo

Research News and Market Data on TZOO

Travelzoo 

Apr 23, 2026, 06:39 ET

NEW YORK, April 23, 2026 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO):

  • Revenue of $24.3 million, up 5% year-over-year
  • Consolidated operating profit of $3.4 million
  • Non-GAAP consolidated operating profit of $3.5 million
  • Cash flow from operations of $3.9 million
  • Earnings per share (EPS) of $0.23

Travelzoo, the club for travel enthusiasts, today announced financial results for the first quarter ended March 31, 2026. Consolidated revenue was $24.3 million, up 5% from $23.1 million year-over-year. In constant currencies, revenue was $23.6 million, up 2% year-over-year. Travelzoo’s reported revenue consists of advertising revenues and commissions, derived from and generated in connection with purchases made by Travelzoo members, and membership fees.

In Q1, we continued to invest significantly in acquiring more Club Members when we saw that we can achieve a positive return on investment (ROI). Marketing costs were expensed immediately. Membership fees revenue is recognized ratably over the subscription period of 12 months. In Q1, the number of renewals of memberships jumped to the highest ever. Because renewals of memberships have no acquisition costs, this had a positive impact on EPS. Going forward, we expect renewals of memberships to further increase because of a growing base of members. We refer to our investor presentation.

Net Income attributable to Travelzoo was $2.5 million for Q1 2026, or $0.23 per share, compared with $0.26 per share in the prior-year period.

Non-GAAP operating profit was $3.5 million. Non-GAAP operating profit excludes stock option expenses ($35,000) and severance expenses ($15,000). Please refer to “Non-GAAP Financial Measures” and the tabular reconciliation below.

“We will continue to leverage Travelzoo’s global reach, trusted brand, and strong relationships with top travel suppliers to negotiate more Club Offers for Club Members and add new benefits, such as our popular complimentary airport lounge access worldwide in case of a delayed flight,” said Holger Bartel, Travelzoo’s Global CEO. “Travelzoo members are affluent, active, and open to new experiences. We inspire travel enthusiasts to travel to places they never imagined they could. Travelzoo is the must-have membership for those who love to travel as much as we do.”

Travelzoo North America
North America business segment revenue increased 4% year-over-year to $15.7 million. Operating profit for Q1 2026 was $3.2 million, or 21% of revenue, compared to operating profit of $3.6 million or 24% of revenue in the prior-year period.

Travelzoo Europe
Europe business segment revenue increased 8% year-over-year to $7.3 million. Operating profit for Q1 2026 was $279,000, or 4% of revenue, compared to operating profit of $228,000, or 3% of revenue in the prior-year period.

Jack’s Flight Club
Jack’s Flight Club is a membership subscription service in which Travelzoo has a 60% ownership interest. Revenue increased 2% year-over-year to $1.3 million. Jack’s Flight Club’s revenue from subscriptions is recognized ratably over the subscription period (quarterly, semi-annually, annually). Operating loss for Q1 2026 was $48,000, compared to operating profit of $12,000 in the prior-year period.

New Initiatives
New Initiatives business segment revenue, which includes Licensing and Travelzoo META, was $17,000. Operating loss for Q1 2026 was $34,000.

In 2020, Travelzoo entered into royalty-bearing licensing agreements with local licensees for the exclusive use of Travelzoo’s brand, business model, and members in Australia, Japan, New Zealand, and Singapore. Under these arrangements, Travelzoo’s existing members in Australia, Japan, New Zealand, and Singapore will continue to be owned by Travelzoo as the licensor. Licensing revenue from the licensee in Australia was $10,000 for Q1 2026. Licensing revenue from the licensee in Japan was $7,000 for Q1 2026. Licensing revenue is expected to increase going forward.

Reach
Travelzoo reaches 30 million travelers. This includes Jack’s Flight Club. Comparisons to prior periods are no longer meaningful due to strategic developments of the Travelzoo membership.

Income Taxes
The reported income tax provision and reserves for Q1 2026 are $942,000. Travelzoo intends to utilize available net operating losses (NOLs) to largely offset its tax liability for Q1 2026.

Balance Sheet
As of March 31, 2026, cash, cash equivalents and restricted cash were $11.3 million. Cash flow from operations was $3.9 million.

Deferred revenue increased because membership fees are earned over the subscription period. Membership fees revenue is recognized ratably over the subscription period.

Share Repurchase Program
During Q1 2026, the Company repurchased 500,000 shares of its outstanding common stock.

Looking Ahead
For Q2 2026, we expect year-over-year revenue growth to continue. We also expect revenue growth in subsequent quarters, as membership fees revenue is recognized ratably over the subscription period of 12 months, as we acquire new members, and as more Legacy Members become Club Members. Over time, we expect profitability to increase as recurring membership fees revenue will be recognized. In the short-term, fluctuations in reported net income are possible. We might see attractive opportunities to increase marketing. We expense marketing costs immediately.

In 2024, we introduced a membership fee for Travelzoo. Legacy Members, who joined prior to 2024, continue to receive certain travel offers. However, Club Offers and new benefits are only available to Club Members, who pay the membership fee. Therefore, we are seeing many Legacy Members become Club Members over time—in addition to new members who join.

Non-GAAP Financial Measures
Management calculates non-GAAP operating income when evaluating the financial performance of the business. Calculation of non-GAAP operating income, also called “non-GAAP operating profit” in this press release and today’s earnings conference call, excludes the following items: amortization of intangibles, stock option expenses, and severance-related expenses. This press release includes a table which reconciles GAAP operating income to the calculation of non-GAAP operating income. Non-GAAP operating income is not required by, or presented in accordance with, generally accepted accounting principles in the United States of America (“GAAP”). This information should be considered as supplemental in nature and should not be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies.

Conference Call
Travelzoo will host a conference call to discuss first quarter 2026 results today at 11:00 a.m. ET. Please visit http://ir.travelzoo.com/events-presentations to

  • download the management presentation (PDF format) to be discussed in the conference call
  • access the webcast.

About Travelzoo
We, Travelzoo®, are the club for travel enthusiasts. We reach 30 million travelers. Club Members receive Club Offers negotiated and rigorously vetted by our deal experts around the globe. Our relationships with thousands of top travel companies give us access to irresistible deals. Our club and its benefits are built around the lifestyle of a modern travel enthusiast.

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include, but are not limited to, statements about our plans, objectives, expectations, prospects and intentions, markets in which we participate and other statements contained in this press release that are not historical facts. When used in this press release, the words “expect”, “predict”, “project”, “anticipate”, “believe”, “estimate”, “intend”, “plan”, “seek” and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including changes in our plans, objectives, expectations, prospects and intentions and other factors discussed in our filings with the SEC. We cannot guarantee any future levels of activity, performance or achievements. Travelzoo undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Investor Relations:
[email protected] 

View full release here.

Helix and Hornbeck Offshore Merge to Build a Deepwater Powerhouse

Posted on by [email protected]

Two of the offshore energy sector’s most recognized names are joining forces. Helix Energy Solutions Group (NYSE: HLX) and Hornbeck Offshore Services have announced a definitive all-stock merger agreement that will create one of the most comprehensive integrated deepwater services companies in the world — and the timing couldn’t be more calculated.

Under the terms of the deal, Hornbeck shareholders will own approximately 55% of the combined company while Helix shareholders retain roughly 45% on a fully diluted basis. The newly formed entity will operate under the Hornbeck Offshore Services name and trade on the New York Stock Exchange under the ticker symbol “HOS.” Todd Hornbeck, currently Chairman, President and CEO of Hornbeck, will lead the combined company, with William Transier serving as Chairman of a seven-member board comprised of three Helix directors and four from Hornbeck.

Why This Deal Makes Strategic Sense

This isn’t a merger of desperation — it’s a merger of expansion. Helix brings deep subsea expertise, well intervention capabilities, and a global robotics fleet with operations spanning the Gulf of America, Brazil, North Sea, West Africa and Asia Pacific. Hornbeck contributes a fleet of technologically advanced, high-specification offshore support vessels with a strong concentration in the Americas, including Brazil and Mexico, along with meaningful exposure to U.S. government and offshore wind contracts.

Together, the combined company covers the entire life cycle of deepwater field operations — from installation and production enhancement to decommissioning — across energy, defense and renewables. That kind of end-to-end service coverage significantly reduces the cyclicality risk that has historically plagued pure-play offshore services companies.

The Numbers Behind the Deal

The transaction is expected to generate $75 million or more in annual revenue and cost synergies within three years of closing. Those synergies will come from integrated service offerings, expanded customer reach and fleet optimization that reduces reliance on expensive third-party vessel charters.

The combined backlog currently stands at approximately $2 billion — split evenly between the two companies — with $1 billion tied to long-term contracts in Hornbeck’s military and specialty vessel segments. That backlog provides meaningful near-term revenue visibility as the integration unfolds.

Helix also reported Q1 2026 revenue of $287.95 million, beating analyst estimates by roughly $24 million, and reiterated full-year 2026 guidance of $1.2 billion to $1.4 billion in revenue with EBITDA projected between $230 million and $290 million. The company closed Q1 with $501 million in cash and just $10 million in funded debt — a balance sheet position that gives the combined entity significant flexibility for organic growth or further M&A post-close.

What to Watch

The merger requires Helix shareholder approval and customary regulatory sign-offs, with closing expected in the second half of 2026. Notably, Ares Management funds, representing a significant portion of Hornbeck’s ownership, have already delivered written consent approving the transaction — removing one of the more common deal-risk variables upfront.

For investors tracking the small and midcap offshore services space, this deal reshapes the competitive landscape. The combined HOS will be a scaled, diversified operator in a sector where scale increasingly determines who wins long-term contracts and who gets squeezed out.

The deepwater services consolidation wave continues — and this merger puts the new Hornbeck Offshore squarely at its center.

Release – Kelly Announces First-Quarter 2026 Conference Call

Posted on by [email protected]

Research News and Market Data on KELYA

April 23, 2026

PDF Version

TROY, Mich., April 23, 2026 (GLOBE NEWSWIRE) — Kelly, a leading global specialty talent solutions provider, will release its first-quarter earnings before the market opens on Thursday, May 7, 2026. In conjunction with its earnings release, Kelly will publish a financial presentation and host a live webcast of a conference call with financial analysts at 9 a.m. ET on May 7 to review the results from the quarter and answer questions.

The presentation and a link to the live webcast will be accessible through the Company’s public website on the Investor Relations page under Events & Presentations. The webcast will be recorded, and a replay will be available within one hour of completion of the event through the same link as the live webcast.

About Kelly

Kelly Services, Inc. (Nasdaq: KELYA, KELYB) helps companies recruit and manage skilled workers and helps job seekers find great work. Since inventing the staffing industry in 1946, we have become experts in the many industries and local and global markets we serve. With a network of suppliers and partners around the world, we connect approximately 375,000 people with work every year. Our suite of outsourcing and consulting services and solutions ensures companies have the people they need, when and where they are needed most. Headquartered in Troy, Michigan, we empower businesses and individuals to access limitless opportunities in industries such as science, engineering, technology, education, manufacturing, retail, finance, and energy. Revenue in 2025 was $4.3 billion. Learn more at kellyservices.com.

KLYA-FIN

Analyst & Media Contacts:
Scott Thomas
(248) 251-7264
[email protected]

Release – Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Posted on by [email protected]

Research News and Market Data on GLSI

 Download as PDF

April 23, 2026 6:00am EDT

STAFFORD, Texas, April 23, 2026 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that an abstract has been accepted for publication at the upcoming 2026 ASCO Annual Meeting along with a corresponding poster presentation.

The 2026 ASCO Annual Meeting will be held from May 28 to June 2, 2026. The full text of the abstract and poster will be available on June 1, 2026, the day of the presentation.

CEO Snehal Patel commented, ” We look forward to meeting many of our principal investigators at the conference. Our abstract will be the second abstract co-authored by the Company and the full Steering Committee of FLAMINGO-01 presenting preliminary injection site reaction immune response data from the non-HLA-A*02 open-label arm.”

In addition to ASCO, the Company plans to attend ESMO Breast, BIO partnering, and investor conferences in the coming months.

About the 2026 ASCO Annual Meeting

ASCO is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer. ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. The ASCO Annual Meeting program features poster presentations, poster discussion sessions, clinical science symposia, and dynamic education sessions about recent advancements in cancer research, treatment, and patient care. For more information, please visit the conference website at: https://conferences.asco.org/am/attend.

About FLAMINGO-01 Open Label Phase III Data

More than 1,300 patients have been screened with a current screen rate of approximately 800 patients per year. The 250 patient non-HLA-A*02 arm is now fully enrolled, where all patients received GLSI-100, which is 5 times more treated patients and recurrence rate data than the approximately 50 patients treated in the Phase IIb trial. The Primary Immunization Series (PIS), which includes the first 6 GLSI-100 injections over the first 6 months and is required to reach peak protection, is followed by 5 booster injections given every 6 months to prolong the immune response, thereby providing longer-term protection.

  • In the non-HLA-A*02 arm, a preliminary analysis of recurrence rates after the PIS is completed shows an approximately 70-80% reduction in recurrence rate.
  • This observation is trending similarly to the Phase IIb trial results and hazard ratio where HLA-A*02 patients were treated and where breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.
  • The immune response at baseline prior to any GLSI-100 treatment, the increasing immune response during the PIS, and the safety profile of non-HLA-A*02 patients is trending similarly to the HLA-A*02 arms of FLAMINGO-01 and to the Phase IIb study.
    • The AACR Meeting 2026 delayed-type-hypersensitivity (DTH) poster can be downloaded here.
    • The frequency of DTH reactions increased by approximately 4x (290%) in the total open-label non-HLA-A*02 population, increasing from 5.2% of the patients experiencing a DTH reaction at baseline, prior to any GLSI-100 administration, to 20.4% of the patients experiencing a DTH reaction in month 4 or month 6 (McNemar, p < 0.001).
    • As reported in Table 1 of the poster, each HLA-A type exhibited more frequent immune reactivity after treatment with GLSI-100 than at baseline with frequency increasing from 100% to 700%.
    • Baseline DTH reaction prior to any treatment suggests that GP2 may be a natural antigen and that GP2 specific T cells may exist in some patients prior to any treatment with GLSI-100. Baseline immune response to GP2 prior to any vaccination with GP2 was also observed in the Phase IIb trial and is being observed in the blinded randomized arms of FLAMINGO-01, where HLA-A*02 only patients are being vaccinated.

Analysis of the open label data from FLAMINGO-01 has been conducted in a manner that maintains the study blind. The open label recurrence rate, immune response, and safety data is based on the patients enrolled to date in FLAMINGO-01 and the data provided by the clinical sites so far, which is not completed or fully reviewed, and is thus preliminary. While comparing any preliminary FLAMINGO-01 data to the Phase IIb clinical trial data may be possible, these preliminary results are not a prediction of future results, and the results at the end of the study may differ.

About GLSI-100 Phase IIb Study

In the prospective, randomized, single-blinded, placebo-controlled, multi-center (16 sites led by MD Anderson Cancer Center) Phase IIb clinical trial of HLA-A*02 breast cancer patients, 46 HER2/neu 3+ over-expressor patients were treated with GLSI-100, and 50 placebo patients were treated with GM-CSF alone. After 5 years of follow-up, there was an 80% or greater reduction in cancer recurrences in the HER2/neu 3+ patients who were treated with GLSI-100, followed, and remained disease free over the first 6 months, which we believe is the time required to reach peak immunity and thus maximum efficacy and protection. The Phase IIb results can be summarized as follows:

  • 80% or greater reduction in metastatic breast cancer recurrence rate over 5 years of follow-up with a peak immune response at 6 months and well-tolerated safety profile.
  • The PIS elicited a potent immune response as measured by local skin tests and immunological assays.

About FLAMINGO-01 and GLSI-100

FLAMINGO-01 (NCT05232916) is a Phase III clinical trial designed to evaluate the safety and efficacy of Fast Track designated GLSI-100 (GP2 + GM-CSF) in HER2 positive breast cancer patients who had residual disease or high-risk pathologic complete response at surgery and who have completed both neoadjuvant and postoperative adjuvant trastuzumab based treatment. The trial is led by Baylor College of Medicine and currently includes US and European clinical sites from university-based hospitals and academic and cooperative networks with plans to open up to 150 sites globally. In the double-blinded arms of the Phase III trial, approximately 500 HLA-A*02 patients are planned to be randomized to GLSI-100 or placebo, and up to 250 patients of other HLA types are planned to be treated with GLSI-100 in a third arm. The trial has been designed to detect a hazard ratio of 0.3 in invasive breast cancer-free survival, where 28 events will be required. An interim analysis for superiority and futility will be conducted when at least half of those events, 14, have occurred. This sample size provides 80% power if the annual rate of events in placebo-treated subjects is 2.4% or greater.

For more information on FLAMINGO-01, please visit the Company’s website here and clinicaltrials.gov here. Contact information and an interactive map of the majority of participating clinical sites can be viewed under the “Contacts and Locations” section. Please note that the interactive map is not viewable on mobile screens. Related questions and participation interest can be emailed to: [email protected]

About Breast Cancer and HER2/neu Positivity

One in eight U.S. women will develop invasive breast cancer over her lifetime, with approximately 300,000 new breast cancer patients and 4 million breast cancer survivors. HER2 (human epidermal growth factor receptor 2) protein is a cell surface receptor protein that is expressed in a variety of common cancers, including in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2 protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, FLAMINGO-01. For more information on Greenwich LifeSciences, please visit the Company’s website at www.greenwichlifesciences.com and follow the Company’s Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in Greenwich LifeSciences’ Annual Report on the most recent Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.

Company Contact
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: [email protected]

Investor & Public Relations Contact for Greenwich LifeSciences
Dave Gentry
RedChip Companies Inc.
Office: 1-800-RED CHIP (733 2447)
Email: [email protected]

Primary Logo

Source: Greenwich LifeSciences, Inc.

Released April 23, 2026

SKYX Platforms (SKYX) – Additional Agreement For European Hospitality Market

Posted on by [email protected]


Thursday, April 23, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Additional Agreement. Hot on the heels of last week’s strategic partnership agreement with Group OTT, SKYX signed an agreement with OTT Heritage Hospitality, a prominent European developer, to deploy and market SKYX’s technologies across the European hotel chains segment and buildings. The new agreement provides additional focus and opportunity for SKYX, in our view, marking another significant step in the Company’s global expansion.

OTT Heritage Hospitality. Also founded by Jean-Francois Ott, OTT Heritage is a real estate company specializing in special situation real estate. The strategy consists of acquiring assets affordably in well-known cities, leveraging their underlying market value. With an investment pipeline of €150-250 million, current projects include a hotel consolidation strategy (objective: 2,000+ rooms) in Lourdes, luxury hospitality in Grasse and Prague, and redevelopment of the legendary Magny-Cours Formula 1 track, with the vision to turn the area into a premier destination for car and motorsport enthusiasts, including racing experiences, hotels, F&B, entertainment, and golf.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Kuya Silver (KUYAF) – Off to a Strong Start in 2026

Posted on by [email protected]


Thursday, April 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong operational start in 2026. Kuya Silver’s first-quarter 2026 results represented a clear inflection point in the ramp-up of its Bethania Silver Project, with record production of 3,076 tonnes and throughput of 100 tonnes per day achieved at the end of March and into early April 2026. Increased mining volumes, along with continued underground development, suggest the operation is scaling efficiently with the buildout of infrastructure needed to support future growth.

Meaningful improvement in grades and recovery rates. Higher grades and improved recovery rates supported a revenue profile heavily weighted to silver, while the planned acquisition of the Camila plant is expected to enhance processing control and efficiency. A cash position of approximately $27 million further strengthens the company’s ability to fund ongoing growth initiatives.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

AZZ (AZZ) – Q4 and FY 2026 Financial Results Exceed Expectations

Posted on by [email protected]


Thursday, April 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fourth quarter and FY 2026 financial results. For FY 2026, AZZ reported adjusted net income of $187.1 million, or $6.19 per share, compared to $156.8 million, or $5.20 per share, during FY 2025, and to our estimate of $182.4 million, or $6.03 per share. Compared to FY 2025, sales increased 4.6% to $1.650 billion. AZZ generated a 23.9% gross margin as a percentage of sales compared to 24.3% during the prior year. Adjusted EBITDA increased to $367.6 million, representing 22.3% of sales, compared to $347.9 million, or 22.0% of sales, in FY 2025. Adjusted net income and EPS during the fourth quarter of FY 2026 were $40.4 million and $1.34, respectively, compared to our estimates of $35.7 million and $1.18 per share. Fourth quarter adjusted EBITDA increased to $81.3 million, representing 21.1% of sales, compared to $71.2 million, or 20.2% of sales, during the prior year period.

Segment results. Compared to the prior year, FY 2026 Metal Coatings sales were up 14.1% to $758.7 million, while Precoat Metals sales were down 2.3% to $891.4 million. Compared to the fourth quarter of FY 2025, fourth quarter Metal Coatings sales were up 25% to $186.5 million, while Precoat Metals sales were down 2.4% to $198.6 million.  Fourth quarter and FY 2026 segment adjusted EBITDA margin amounted to 30.2% and 31.0%, respectively, for Metal Coatings, and 18.2% and 19.8% for Precoat Metals.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

The AI Purge: What Big Tech’s Job Cuts Really Signal for Small Cap Markets

Posted on by [email protected]

The wave is no longer building — it has made landfall. In the span of a single week, Meta announced it is cutting 10% of its workforce (roughly 8,000 employees), Microsoft launched a voluntary buyout program targeting approximately 7% of its U.S. staff, and Snap disclosed a 16% reduction — about 1,000 jobs — all under the banner of AI-driven efficiency. Add Amazon, Oracle, Block, and Salesforce to the list, and the message from corporate America’s biggest names is unmistakable: AI is now a cost-cutting weapon, and human headcount is the first casualty.

Meta, Microsoft, Amazon, and Google alone are projected to spend approximately $650 billion in capital expenditures in 2026. The paradox? The same technology they claim is unlocking productivity is also justifying mass layoffs. Snap’s leadership framed their cuts as enabling faster, leaner squads. Block’s CEO publicly attributed a 40% workforce reduction to the deployment of internal intelligence tools. Salesforce pointed to AI coding agents replacing the need for human engineers. The narrative is consistent enough to raise a pointed question: is this genuine transformation, or a convenient cover for margin repair?

For small and microcap investors, the implications cut deeper than headline risk on large-cap tech stocks.

First, AI adoption no longer belongs exclusively to companies with multi-billion-dollar R&D budgets. The same tools that Meta and Microsoft are deploying internally are increasingly available to smaller operators — often through the very platforms Big Tech is building. That’s a real competitive leveler. Small and microcap companies that move early on AI integration stand to compress their cost structures in ways that could dramatically re-rate their earnings profiles.

Second, the displacement of tens of thousands of skilled tech workers creates a talent pipeline that smaller companies can now access. Engineers, product managers, and data scientists who previously would have never considered a company with a sub-$500 million market cap are suddenly in the job market — and often more open to equity-heavy compensation packages. For growth-stage small caps, that is a structural recruiting opportunity.

Third, and perhaps most importantly for investors, Big Tech’s AI spending spree is creating a robust ecosystem of beneficiaries across the supply chain — many of them small and microcap companies. Infrastructure build-out at this scale drives demand for specialized hardware, cooling technology, energy solutions, cybersecurity tools, and vertical AI software providers. These are not household names. They are precisely the kind of companies that ChannelChek and Noble Capital Markets exist to surface.

The layoff headlines are really a signal about where capital is flowing, not just where jobs are disappearing. The companies being cut from the org charts of Menlo Park and Redmond are not the story. The companies quietly building the infrastructure that enables those cuts — and the smaller operators sharp enough to ride the same wave — are where the real opportunity lives.

The AI efficiency era has arrived. The question for small cap investors is whether they are positioned to benefit from it or simply watching it unfold from the sidelines.